Home › Compare › CBLRF vs MRK

CBLRF vs MRK: Dividend Comparison 2026

CBLRF yields 20000000.00% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CBLRF wins by $4.875981653489057e+49M in total portfolio value
10 years
CBLRF
CBLRF
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full CBLRF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — CBLRF vs MRK

📍 CBLRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBLRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBLRF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CBLRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBLRF
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, CBLRF beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBLRF + MRK for your $10,000?

CBLRF: 50%MRK: 50%
100% MRK50/50100% CBLRF
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CBLRF
No analyst data
Altman Z
-7.2
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBLRF buys
0
MRK buys
0
No recent congressional trades found for CBLRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBLRFMRK
Forward yield20000000.00% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$4.875981653489057e+49M$30.7K ✓
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$950.29
Total dividends collected$4.875978515990276e+49M$6.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CBLRF vs MRK ($10,000, DRIP)

YearCBLRF PortfolioCBLRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$11,192$351.54+$2000.00M → CBLRF
2$373,835,915,712,384$373,833,775,700,934.50$12,524$392.70+$373835915.70M → CBLRF
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$14,015$438.65+$65304953364964.95M → CBLRF
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$15,682$489.96+$10661728832755499008.00M → CBLRF
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$17,547$547.23+$1.626767783781495e+24M → CBLRF
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$19,632$611.16+$2.319743300546251e+29M → CBLRF
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$21,963$682.53+$3.0915106403922057e+34M → CBLRF
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$24,571$762.18+$3.8505079858392777e+39M → CBLRF
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$27,486$851.08+$4.4821026103531426e+44M → CBLRF
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$30,745$950.29+$4.875981653489057e+49M → CBLRF

CBLRF vs MRK: Complete Analysis 2026

CBLRF — Stock

Campbell Resources Inc. engages in the development and exploitation of copper and gold mining properties in the Chibougamau region of Quebec. It holds interests primarily in the Corner Bay property, which is located approximately 55 kilometers south of the city of Chibougamau, Quebec. The company was founded in 1950 and is headquartered in Montreal, Canada. On January 28, 2009, Campbell Resources Inc. filed for protection under the Companies' Creditors Arrangement Act in the Superior Court of Quebec.

Full CBLRF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this CBLRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBLRF vs SCHDCBLRF vs JEPICBLRF vs OCBLRF vs KOCBLRF vs MAINCBLRF vs JNJCBLRF vs ABBVCBLRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.